Douglas G. Batt
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Douglas G. Batt has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
Dilip P. Modi
DuPont Pharmaceuticals Company, P.O. Box 80500, Wilmington, Delaware 19880-0500
1 shared publicationFrank A. Barbera
DuPont Pharmaceuticals Company, P.O. Box 80500, Wilmington, Delaware 19880-0500
1 shared publicationGary A. Cain
DuPont Pharmaceuticals Company, P.O. Box 80500, Wilmington, Delaware 19880-0500
1 shared publicationGregory C. Houghton
DuPont Pharmaceuticals Company, P.O. Box 80500, Wilmington, Delaware 19880-0500
1 shared publicationJoseph J. Petraitis
DuPont Pharmaceuticals Company, P.O. Box 80500, Wilmington, Delaware 19880-0500
1 shared publicationMark S. Forsythe
DuPont Pharmaceuticals Company, P.O. Box 80500, Wilmington, Delaware 19880-0500
1 shared publication
Latest Publications
- 16 December 1999
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 43 (1) , 41-58
Disubstituted Indazoles as Potent Antagonists of the Integrin αvβ3
A new series of indazole-containing αvβ3 integrin antagonists is described. Starting with lead compound 18a, variations in a number of structural features were explored with respect to inhibition of the binding of β3-transfected 293 cells to fibrinogen and to selectivity for αvβ3 over GPIIbIIIa, another RGD-binding integrin. Indazoles attached to a 2-aminopyridine or 2-aminoimidazole by a propylene linker at the indazole 1-position and to a diaminopropionate derivative via a 5-carboxylate amide provided the best potency with moderate selectivity. Several differences in the SAR of the diaminopropionate moiety were observed between this series and a series of isoxazoline-based selective GPIIbIIIa antagonists. Compound 34a (SM256) was a potent antagonist of αvβ3 (IC50 2.3 nM) with 9-fold selectivity over GPIIbIIIa.
- 16 December 1999
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 43 (1) , 41-58
Disubstituted Indazoles as Potent Antagonists of the Integrin αvβ3
A new series of indazole-containing αvβ3 integrin antagonists is described. Starting with lead compound 18a, variations in a number of structural features were explored with respect to inhibition of the binding of β3-transfected 293 cells to fibrinogen and to selectivity for αvβ3 over GPIIbIIIa, another RGD-binding integrin. Indazoles attached to a 2-aminopyridine or 2-aminoimidazole by a propylene linker at the indazole 1-position and to a diaminopropionate derivative via a 5-carboxylate amide provided the best potency with moderate selectivity. Several differences in the SAR of the diaminopropionate moiety were observed between this series and a series of isoxazoline-based selective GPIIbIIIa antagonists. Compound 34a (SM256) was a potent antagonist of αvβ3 (IC50 2.3 nM) with 9-fold selectivity over GPIIbIIIa.